BioCryst Pharmaceuticals, Inc. (BCRX) Jefferies London Healthcare Conference 2025 November 19, 2025 12:00 PM EST
Company Participants
Jon Stonehouse – CEO & Executive Director
Charles Gayer – President & Chief Commercial Officer
Babar Ghias – CFO & Head of Corporate Development
Conference Call Participants
Maurice Raycroft – Jefferies LLC, Research Division
Presentation
Maurice Raycroft
Jefferies LLC, Research Division
Hi, everyone. My name is Maury Raycroft, and I’m one of the biotech analysts at Jefferies. It’s with great pleasure that I’d like to welcome the BioCryst’s management team. We’ve got Jon Stonehouse, CEO; Charles Gayer, Chief Commercial Officer; and Babar Ghias, the CFO. Thanks so much for joining us today.
Jon Stonehouse
CEO & Executive Director
Yes. Thanks for having us.
Maurice Raycroft
Jefferies LLC, Research Division
And we’re going to do a fireside chat format. So for those who are new to the story, if you can give a brief intro to BioCryst.
Jon Stonehouse
CEO & Executive Director
Sure. So Maury, first off, thanks for inviting us to this year’s conference. We’re all going to be making forward-looking statements. Those statements have risks. Risk factors can be found in our most recent filings.
BioCryst is a pretty interesting company. I’ve been in it for almost 19 years. And today, BioCryst is a company with revenue from ORLADEYO, somewhere between $590 million and $600 million and growing to a peak of $1 billion. So really good trajectory of growth and patent protection out to 2040. So that’s the growth engine.
Next is we’ve got a pipeline of internal stuff, the one that’s in the clinic — 2 in the clinic, [ 17725 ] for Netherton and then avoralstat for DME.
And then third, we’re in a financial situation where we were able to do a proposed acquisition with Astria, and that’s in the
Credit: Source link
